Medulloblastoma (MB) is the most common malignant pediatric brain tumor. The MYC‑amplified group 3 (G3) MB represents a high‑risk disease lacking effective therapies. A genetic screen identified the endoplasmic reticulum chaperone HSPA5 (BiP/GRP78) as a critical dependency in G3 MB. Its silencing induces apoptosis and...
Liliana Mirabal-Ortega, Sandra Majo, Lucie J. Taunay et al.· Nature Communications· 0 citations
BACKGROUND
MEK inhibition has demonstrated activity in pediatric low-grade gliomas (pLGGs) driven by BRAF rearrangements, but data on trametinib remain limited, regarding efficacy, short and long-term toxicities.
METHODS
We conducted a retrospective multicenter study of patients with BRAF-rearranged non NF1 pLGGs rec...
Céline Khouri, Amandine Bibollet, Y. Bouchoucha et al.· European Journal of Cancer· 0 citations
INTRODUCTION
Next-generation sequencing performed for therapeutic decision-making in pediatric cancers provides an opportunity to identify germline variants associated with hereditary cancer predisposition and other actionable inherited conditions.
METHODS
Germline whole-exome sequencing (WES) was performed within th...
Tiphaine Adam-de-Beaumais, Y. Adnani, L. Guerrini-Rousseau et al.· European Journal of Cancer· 0 citations
PURPOSE
Rhabdoid tumors (RTs) are highly aggressive pediatric cancers driven by the biallelic inactivation of the SMARCB1 tumor suppressor gene, the sole recurrent genetic alteration. SMARCB1 encodes a core subunit of the SWI/SNF chromatin remodeling complex; its loss disrupts epigenetic gene regulation, supporting the...
C. Chauvin, Ryszard Wimmer, Ludovica Brunetti et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.